According to DelveInsight analysis, the Dystrophic Epidermolysis Bullosa market is expected to witness significant growth between 2024 and 2034 |Major players include Krystal Biotech, Chiesi, Phoenix Therapeutics, Aegle Therapeutics, Anterogen, and others.

Prominent Dystrophic Epidermolysis Bullosa market participants include Krystal Biotech, Chiesi, Phoenix Therapeutics, Aegle Therapeutics, Anterogen Co., Abeona Therapeutics, Inc, Castle Creek Bioscience, Phoenix Tissue Repair, Inc., Scioderm, Inc., InMed Pharmaceuticals, and others.

DelveInsight's comprehensive report, "Dystrophic Epidermolysis Bullosa Market Insights, Epidemiology, and Market Forecast-2034," provides a detailed analysis of dystrophic epidermolysis bullosa, including historical and forecasted epidemiology data and market trends across the US, EU4 (Germany, Spain, Italy, France), UK, and Japan.

For comprehensive information on the dystrophic epidermolysis bullosa market outlook, drug adoption, treatment status, and epidemiological patterns, please visit:Dystrophic Epidermolysis Bullosa Market Forecast 。

Key highlights of the Dystrophic Epidermolysis Bullosa market report:

• The Dystrophic Epidermolysis Bullosa market is projected to expand at a remarkable CAGR throughout the study period (2020-2034)

• In February 2025, Ligand Pharmaceuticals, Inc. (Nasdaq: LGND) entered into a royalty financing agreement with Castle Creek Biosciences, Inc. to support Phase 3 clinical trials of D-Fi (FCX-007), its lead candidate for the treatment of dystrophic epidermolysis bullosa (DEB).

• In November 2024, Abeona Therapeutics Inc. (Nasdaq: ABEO) disclosed that the U.S. Food and Drug Administration (FDA) had accepted its resubmitted Biologics License Application (BLA) for prademagen zamiceracel (pz-cel), an investigational autologous cell-based gene therapy being evaluated as a potential treatment for recessive dystrophic epidermolysis bullosa (RDEB).

• The overall 7MM dystrophic epidermolysis bullosa market size is expected to be approximately USD 550 million in 2023, growing during the forecast period.

• In 2023, the US dominated the 7MM market with around USD 400 million.

• Within the EU4 and UK region, the UK is the largest market for dystrophic epidermolysis bullosa, with a size of approximately US$50 million.

• Spain had the smallest dystrophic epidermolysis bullosa market size in the 7MM, totaling approximately USD 20 million.

• Overall in the 7MM, there were approximately 6,500 endemic cases of dystrophic epidermolysis bullosa diagnosed in 2023, of which the United States accounted for approximately 3,500 cases, or about 50% of the total.

• The age group most affected by dystrophic epidermolysis bullosa in 2023 was children aged 1 to 9 years, with approximately 1,300 cases reported.

• Major companies in the field of heterotrophic epidermal bullous disease: Krystal Biotech, Chiesi, Phoenicis Therapeutics, Aegle Therapeutics, Anterogen Co., Ltd., Abeona Therapeutics, Inc, Castle Creek Bioscience, Phoenix Tissue Repair, Inc., Scioderm, Inc., InMed Pharmaceuticals Inc.

• Main dystrophic epidermolysis bullosa treatments: VYJUVEK (beremagene geperpavec), FILSUVEZ (birch triterpene), PTW-002 10 mg/g gel, AGLE 102, ALLO-ASC-SHEET, EB-101, FCX-007, PTR-001 SD-101-6.0 cream, INM-755 (cannabinol) cream, etc.

• Epidemiological analysis by type shows that the number of cases of dominant dystrophic epidermolysis bullosa slightly exceeds the number of cases of recessive dystrophic epidermolysis bullosa.

• The dystrophic epidermolysis bullosa market is expected to expand due to the increasing prevalence and awareness of the disease during the forecast period. Moreover, the introduction of various pipeline products at various stages of development will significantly alter the dynamics of the dystrophic epidermolysis bullosa market.

Overview of Dystrophic Epidermolysis Bullosa

Dystrophic epidermolysis bullosa (DEB) is a rare genetic skin disorder characterized by delicate skin that is prone to blistering and bruising, often triggered by minor friction or trauma. It is caused by mutations in collagen genes, specifically COL7A1, which cause a deficiency or dysfunction of type VII collagen, which is important for binding skin layers together. DEB varies in severity, and symptoms range from mild skin fragility to severe complications such as scarring, disfigurement, increased risk of skin infections, and skin cancer. There is currently no cure, so treatment focuses on wound management, pain management, and prevention of complications.

Request a free sample of Dystrophic Epidermolysis Bullosa Market Forecast, Size & Share Analysis Report: https://www.delveinsight.com/report-store/dystrophic-epidermoosis-bullosa-market

Epidemiology of dystrophic epidermolysis bullosa

The epidemiology section provides insights into the past, current, and projected epidemiological trends across seven major markets (7MM) from 2020 to 2034. It helps identify the causes of current and projected patterns by examining numerous studies and the perspectives of key opinion leaders. The section also provides a detailed analysis of diagnosed patient populations and future trends.

Epidemiological segmentation of dystrophic epidermolysis bullosa:

The Dystrophic Epidermolysis Bullosa Market report provides an epidemiological analysis for the study period 2020-2034 in the 7MM, segmented as follows:

• Total prevalence of dystrophic epidermolysis bullosa

• Prevalent cases of dystrophic epidermolysis bullosa classified by severity

• Gender-specific prevalence of dystrophic epidermolysis bullosa

• Cases diagnosed as episodic and chronic dystrophic epidermolysis bullosa

Download the report to understand factors driving epidemiological trends in dystrophic epidermolysis bullosa.Epidemiological prediction of dystrophic epidermolysis bullosa

Dystrophic Epidermolysis Bullosa Drug Uptake and Pipeline Development Activity

The drug uptake section examines the recently launched and expected drug adoption rate in the Dystrophic Epidermolysis Bullosa market during the study period. The analysis covers market uptake by drug, patient adoption by treatment modality, and sales performance of each drug.

Additionally, the therapeutic drug evaluation section helps you understand which drugs are gaining the fastest uptake and the reasons behind their maximum utilization. It also compares drugs based on their market share.

The report also covers the Dystrophic Epidermolysis Bullosa pipeline development activities and provides valuable information on key companies developing potential therapeutics and targeted therapies at various stages. It also analyzes recent developments including collaborations, acquisitions, mergers, patent licensing details, and other information on novel treatments.

Dystrophic Epidermolysis Bullosa Treatments and Key Companies

• VYJUVEK (bermagene geperpavec): Crystal Biotech

• FILSUVEZ (Birch Triterpenes): Chiesi

• PTW-002 10 mg/g Prescription: Phoenicis Therapeutics

• AGLE 102: AGLE Therapeutics

• ALLO-ASC-SHEET: Antelogen Co., Ltd.

• EB-101: Abeona Therapeutics, Inc.

• FCX-007: Castle Creek Biosciences

• PTR-01: Phoenix Tissue Repair Co., Ltd.

• SD-101-6.0 Cream: Cyderm Co., Ltd.

• INM-755 (Cannabinol) Cream: InMed Pharmaceuticals Inc.

Learn more about the treatments that can capture a significant share of the Dystrophic Epidermolysis Bullosa market @Treatment for dystrophic epidermolysis bullosa

Strengths of the Dystrophic Epidermolysis Bullosa Market

• An increasing number of clinical trials are evaluating innovative therapeutic approaches that have the potential to modify the progression of dystrophic epidermolysis bullosa and reduce symptoms.

• Gene therapy for dystrophic epidermolysis bullosa is becoming a reality with VYJUVEK approved as first FDA-approved topical gene therapy

Market Opportunity for Dystrophic Epidermolysis Bullosa

• Currently, there is no cure and only limited approved treatments, creating significant commercial opportunities for companies developing regenerative medicines, particularly cell and gene therapies.

• Important advances in understanding the molecular genetics and pathological mechanisms of dystrophic epidermolysis bullosa have established the basis for developing potential treatments.

Scope of the Dystrophic Epidermolysis Bullosa Market Report

• Research period: 2020-2034

• Coverage: 7MM [US, EU5 (Germany, France, Italy, Spain, UK), and Japan]

• Major companies involved in the treatment of hemolytic angiotensin II bullosa include Krystal Biotech, Chiesi, Phoenix Therapeutics, Aegle Therapeutics, Anterogen Co., Ltd., Abeona Therapeutics, Inc, Castle Creek Bioscience, Phoenix Tissue Repair, Inc., Scioderm, Inc., and InMed Pharmaceuticals Inc.

• Major dystrophic epidermolysis bullosa treatments: VYJUVEK (beremagene geperpavec), FILSUVEZ (birch triterpenes), PTW-002 10 mg/g gel, AGLE 102, ALLO-ASC-SHEET, EB-101, FCX-007, PTR-001, PTR-016. cream, INM-755 (cannabinol) cream, etc.

• Treatment evaluation of dystrophic epidermolysis bullosa: current marketed and emerging therapies

• Dystrophic Epidermolysis Bullosa Market Dynamics: Market Drivers and Barriers

• Competitive intelligence analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG matrix, market entry strategy

• Dystrophic Epidermolysis Bullosa Unmet Needs, KOL Opinions, Analyst Perspectives, Market Access & Reimbursement

For more information about companies working to treat dystrophic epidermolysis bullosa, visit @Clinical trials and treatment evaluation for dystrophic epidermolysis bullosa

table of contents

1. Introduction of Dystrophic Epidermolysis Bullosa Market Report

2. Summary on Dystrophic Epidermolysis Bullosa

3. SWOT analysis of dystrophic epidermolysis bullosa

4. Overview of Percentage of Patients with Dystrophic Epidermolysis Bullosa

5. Dystrophic Epidermolysis Bullosa Market Overview

6. Background and Overview of Dystrophic Epidermolysis Bullosa

7. Epidemiology and patient population of dystrophic epidermolysis bullosa

8. Dystrophic epidermolysis bullosa patient population by country

9. Current treatments and medical procedures for dystrophic epidermolysis bullosa

10. Unmet needs in dystrophic epidermolysis bullosa

11. A new treatment for dystrophic epidermolysis bullosa

12. Dystrophic Epidermolysis Bullosa Market Outlook

13. Dystrophic Epidermolysis Bullosa Market Analysis by Country (2020–2034)

14. Market Access and Reimbursement for Treatment of Dystrophic Epidermolysis Bullosa

15. Market Drivers of Dystrophic Epidermolysis Bullosa

16. Dystrophic Epidermolysis Bullosa Market Barriers

17. Dystrophic epidermolysis bullosa appendix

18. Methodology of Dystrophic Epidermolysis Bullosa Report

19. DelveInsight Features

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading healthcare business consultancy and market research organization focused on life sciences. The company supports pharmaceutical businesses by providing end-to-end solutions to improve performance. It also offers healthcare consulting services that help in market analysis to accelerate business growth and overcome challenges with a practical approach.